Recombinant human growth hormone and rosiglitazone for abdominal fat accumulation in HIV-infected patients with insulin resistance: a randomized, double-blind, placebo-controlled, factorial trial.

PLoS One · 2013 · PMC3625151 · PMID 23593417

Europe PMC DOI

hedged sentence

0.0940

closest p · 1.9× alpha

0.0940

boldest claim

The sentences

borderline significantP = 0.094so close (0.05 < p ≤ 0.1)

By 2-way ANCOVA, the rhGH x rosiglitazone interaction was borderline significant (P = 0.094).

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.